3-(2-Fluoro-6-nitrophenyl)propanoic acid | 132715-74-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(2-Fluoro-6-nitrophenyl)propanoic acid
• 英文别名: 3-(2-fluoro-6-nitrophenyl)propionic acid
• CAS: 132715-74-3
• 化学式: C₉H₈FNO₄
• 分子量: 213.165
• InChiKey: UXGZRFLRSRSIAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(2-Fluoro-6-nitrophenyl)propanoic acid 在 钯 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to afford 5-Fluoro-3,4-dihydroquinolin-2(1H)-one (4.6 g) as a slightly brown solid的产率得到5-氟-3,4-二氢-1H-喹啉-2-酮
  参考文献：
  名称：

  3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists

  摘要：

  本发明提供一种化合物，其为（R）-6-[2-[4-(3-氟苯基)-4-羟基-1-哌啶基]-1-羟乙基]-3,4-二氢-2(1H)-喹啉酮或其药学上可接受的酯，或其药学上可接受的盐。该化合物可用于治疗由NMDA NR2B受体过度激活引起的疾病状态，如疼痛、中风、创伤性脑损伤、帕金森病、阿尔茨海默病、抑郁症、焦虑症、偏头痛等哺乳动物，尤其是人类。本发明还提供了包括上述化合物的制药组合物。

  公开号：

  US20030216430A1
• 作为产物：
  描述：

  2-氟-6-硝基溴苄 在 盐酸 、 水 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.67h， 生成 3-(2-Fluoro-6-nitrophenyl)propanoic acid
  参考文献：
  名称：

  [EN] NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS
  [FR] NOUVEAUX CARBOXAMIDES HÉTÉROCYCLIQUES COMME AGONISTES DE M1

  摘要：

  本发明涉及式(I)的新型M1激动化合物及其在治疗与精神分裂症等疾病相关的认知障碍以及在治疗其他通过胆碱能M1受体介导的疾病中的应用。

  公开号：

  WO2009106534A1

文献信息

• [EN] FUSED LACTAM COMPOUNDS<br/>[FR] COMPOSES DE LACTAME CONDENSE
  申请人：PFIZER JAPAN INC

  公开号：WO2005035523A1

  公开（公告）日：2005-04-21

  This invention provides a compound the formula (I), wherein R1 represents an aryl group having from 6 to 10 ring carbon atoms etc.; R2 represents a hydrogen atom etc., n epresents 0, 1 or 2; said heteroaryl group is unsubstituted or substituted and said ary is substituted by at least one substituer,t selected from the group consisting of substituents a; said substituents a are selected from the group 10 consisting of halogen ate ms, alkyl groups having from 1 to 6 carbon atoms etc.; or a pharmaceutically ac eptable ester of such compound, or a pharmaceutically ac eptable salt thereof. These compou ds are useful for the treatment of disease conditions caused 15 by overactivation of N DA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composi ion comprising the above compound.

  本发明提供了一种具有公式(I)的化合物，其中R1代表一个具有6到10个环碳原子的芳基团等；R2代表一个氢原子等，n代表0、1或2；所说的杂芳基团未取代或取代，所说的芳基至少被一个从由取代基a组成的组中选择的取代基t所取代；所说的取代基a是从由卤素原子、具有1到6个碳原子的烷基团等组成的组中选择的；或者该化合物的药物可接受的酯，或者其药物可接受的盐。这些化合物用于治疗由NDA NR2B受体过度激活引起的疾病状况，如疼痛、中风、创伤性脑损伤、帕金森病、阿尔茨海默病、抑郁症、焦虑症、偏头痛或类似疾病，特别是在哺乳动物中，特别是人类。本发明还提供了一种包含上述化合物的药物组合物。
• 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
  申请人：Pfizer, Inc.

  公开号：US06713490B2

  公开（公告）日：2004-03-30

  This invention provides a compound which is (R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. The compound is useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一种化合物，即(R)-6-[2-[4-(3-氟苯基)-4-羟基-1-哌啶基]-1-羟基乙基]-3,4-二氢-2(1H)-喹啉酮或其药学上可接受的酯或其药学上可接受的盐。该化合物可用于治疗由NMDA NR2B受体过度激活引起的疾病，如疼痛、中风、创伤性脑损伤、帕金森病、阿尔茨海默病、抑郁症、焦虑症、偏头痛等哺乳动物，特别是人类。本发明还提供了包含上述化合物的药物组合物。
• McKittrick, Brian; Failli, Amedeo; Steffan, Robert J., Journal of Heterocyclic Chemistry, 1990, vol. 27, # 7, p. 2151 - 2163
  作者：McKittrick, Brian、Failli, Amedeo、Steffan, Robert J.、Soll, Richard M.、Hughes, Philip、et al.

  DOI：——

  日期：——
• Discovery of <i>N</i>-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M₁ Receptor Agonist with Unprecedented Selectivity and Procognitive Potential
  作者：Anette G. Sams、Morten Hentzer、Gitte K. Mikkelsen、Krestian Larsen、Christoffer Bundgaard、Niels Plath、Claus T. Christoffersen、Benny Bang-Andersen

  DOI：10.1021/jm100697g

  日期：2010.9.9

  The discovery and structure activity relationship (SAR) of a series of allosteric muscarinic M, receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M-1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.
• 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS
  申请人：PFIZER INC.

  公开号：EP1499606A1

  公开（公告）日：2005-01-26